Received a Notice of Authorization from the Therapeutic Products Directorate, Health Canada, for its planned clinical trial for PhytoPain Topical Gel Relief Being developed as a locally administered therapeutic for the treatment of Chemotherapy-Induced Neuropathic Pain OTTAWA, ONTARIO-(Feb. 1, 2017) - PhytoPain Pharma Inc. (“PPP”), a subsidiary of Tetra Bio-Pharma (“ Tetra ” or the “ Company “) (CSE:TBP), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has received a Notice of Authorization from the Therapeutic Products Directorate, Health Canada, for its planned clinical trial for PhytoPain Topical ...
Read More